Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Editas: Q2 Earnings Snapshot AP - Wed Aug 5, 4:04PM CDT

Editas: Q2 Earnings Snapshot

EDIT : 3.35 (+2.13%)
Editas Medicine Announces Second Quarter 2026 Results and Business Updates GlobeNewswire - Wed Aug 5, 3:01PM CDT

EDIT-401 on track for CTN submission this month with data update in Q1 2027

EDIT : 3.35 (+2.13%)
Editas Medicine Announces Second Quarter 2026 Results and Business Updates GlobeNewswire - Wed Aug 5, 3:01PM CDT

EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,...

EDIT : 3.35 (+2.13%)
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. GlobeNewswire - Tue Aug 4, 3:15PM CDT

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) --  Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 3.35 (+2.13%)
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference GlobeNewswire - Thu May 28, 3:01PM CDT

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced...

EDIT : 3.35 (+2.13%)
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference GlobeNewswire - Thu May 28, 3:01PM CDT

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing...

EDIT : 3.35 (+2.13%)
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering GlobeNewswire - Tue May 26, 8:05AM CDT

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the...

EDIT : 3.35 (+2.13%)
Editas Medicine Announces Proposed Public Offering GlobeNewswire - Tue May 26, 5:15AM CDT

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that...

EDIT : 3.35 (+2.13%)
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress GlobeNewswire - Tue May 26, 5:01AM CDT

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent...

EDIT : 3.35 (+2.13%)
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting GlobeNewswire - Thu May 14, 5:01AM CDT

CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical...

EDIT : 3.35 (+2.13%)

Barchart Exclusives

Quantum Stocks Looked Like Nvidia in 2019. Then They Belly-Flopped 50%. Barchart - 1 hour ago
Quantum stocks crashed around 50%, but IonQ raised guidance while Rigetti and D-Wave held key strengths. The selloff may have created a new opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.